Kovack Advisors’s Humacyte HUMA Stock Holding History

Kovack Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.5K	Buy	82,600 +10,000	+14%	+$9.27K	﹤0.01%	1055
2026 Q1	$44K	Hold	72,600	–	–	﹤0.01%	996
2025 Q4	$69.7K	Buy	+72,600	New	+$103K	﹤0.01%	995
2023 Q4	–	Sell	-42,000	Closed	-$123K	–	590
2023 Q3	$123K	Buy	42,000 +2,000	+5%	+$6.62K	0.02%	524
2023 Q2	$114K	Buy	40,000 +5,000	+14%	+$18K	0.01%	550
2023 Q1	$108K	Buy	35,000 +10,000	+40%	+$28.4K	0.01%	553
2022 Q4	$52.8K	Buy	+25,000	New	+$75.9K	0.01%	531
2022 Q2	–	Sell	-31,500	Closed	-$222K	–	670
2022 Q1	$222K	Buy	+31,500	New	+$183K	0.02%	624

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Kovack Advisors's HUMA Position: Q2 2026 in Review

Kovack Advisors increased its Humacyte (HUMA) stake by 14% in Q2 2026, buying an estimated $9.27K and bringing the position to 82,600 shares worth $64.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1055.

Kovack Advisors first reported a position in HUMA in Q1 2022 and has held it in 8 quarters since. The position peaked at $222K in Q1 2022. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Kovack Advisors held 82,600 shares of Humacyte worth $64.5K as of Q2 2026.
Kovack Advisors bought 10,000 Humacyte shares in Q2 2026, an estimated $9.27K.
Humacyte made up ﹤0.01% of Kovack Advisors's portfolio in Q2 2026, its #1055 holding.
Kovack Advisors first reported a position in Humacyte in Q1 2022 and has held it in 8 quarters since.
Kovack Advisors's Humacyte position peaked at $222K in Q1 2022.
163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.